ZyCoV-D vaccine pricing close to being finalised, says Mandaviya

The RNA-based vaccine, meant for the age group of 12 to 18 besides adults, got the Emergency Use Authorisation from the drug regulator on August 20.

Mansukh L Mandaviya
Union Health Minister Mansukh L Mandaviya | File photo
IANS New Delhi
1 min read Last Updated : Oct 26 2021 | 7:13 PM IST

Ongoing discussions on pricing of children's vaccine ZyCoV-D are in their last stage, and it will be rolled out soon, Union Health Minister Mansukh Mandaviya said on Tuesda.

The RNA-based vaccine, meant for the age group of 12 to 18 besides adults, got the Emergency Use Authorisation from the drug regulator on August 20.

About the WHO's EUL approval to India's indigenous vaccine Covaxin, he said that the technical team of global health body has approved it, and the "other committee is meeting today which will decide on the approval of the vaccine".

On the question on new Covid variant AY 4.2, Mandaviya said that at this time, nothing can be said about the severity of the variant. A team of the Indian Council for Medical Research and the National Centre for Disease Control are investigating and analysing the different variants, he added,

Addressing a press conference here on recently launched Ayushman Bharat Pradhan Mantri Health Infrastructure Mission, he said that the ongoing Covid pandemic gave an opportunity to improve the health infrastructure.

--IANS

avr/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineMansukh Lal Mandaviya

First Published: Oct 26 2021 | 7:11 PM IST

Next Story